247,000 Shares in Bristol-Myers Squibb (NYSE:BMY) Bought by BLI Banque de Luxembourg Investments

BLI Banque de Luxembourg Investments acquired a new stake in shares of Bristol-Myers Squibb (NYSE:BMY) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 247,000 shares of the biopharmaceutical company’s stock, valued at approximately $13,848,000.

Several other hedge funds also recently added to or reduced their stakes in BMY. Algert Global LLC grew its stake in Bristol-Myers Squibb by 4.2% in the fourth quarter. Algert Global LLC now owns 103,575 shares of the biopharmaceutical company’s stock worth $5,858,000 after purchasing an additional 4,219 shares in the last quarter. Ameriprise Financial Inc. grew its position in shares of Bristol-Myers Squibb by 59.9% in the 4th quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company’s stock worth $1,814,341,000 after acquiring an additional 12,011,983 shares in the last quarter. Ancora Advisors LLC increased its holdings in shares of Bristol-Myers Squibb by 5.2% in the 4th quarter. Ancora Advisors LLC now owns 30,655 shares of the biopharmaceutical company’s stock valued at $1,734,000 after acquiring an additional 1,528 shares during the last quarter. Anderson Financial Strategies LLC acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at approximately $147,000. Finally, Aptus Capital Advisors LLC lifted its stake in Bristol-Myers Squibb by 1,221.2% during the fourth quarter. Aptus Capital Advisors LLC now owns 287,206 shares of the biopharmaceutical company’s stock worth $16,244,000 after purchasing an additional 265,468 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the acquisition, the executive vice president now owns 83,513 shares of the company’s stock, valued at approximately $3,973,548.54. This represents a 5.36 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.09% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Piper Sandler began coverage on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $65.00 price objective on the stock. Cantor Fitzgerald reiterated a “neutral” rating and set a $55.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. UBS Group reduced their price objective on Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a research report on Friday, April 11th. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Friday, April 25th. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $55.00 price target (down previously from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $58.00.

Bristol-Myers Squibb Trading Up 1.9 %

Bristol-Myers Squibb stock opened at $50.56 on Friday. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33. The stock has a market capitalization of $102.89 billion, a PE ratio of -11.44, a price-to-earnings-growth ratio of 2.07 and a beta of 0.41. The firm has a 50 day simple moving average of $55.68 and a 200-day simple moving average of $56.39. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.30. The company had revenue of $11.20 billion for the quarter, compared to analysts’ expectations of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm’s revenue for the quarter was down 5.6% on a year-over-year basis. During the same period last year, the firm earned ($4.40) EPS. As a group, equities research analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were given a dividend of $0.62 per share. The ex-dividend date of this dividend was Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 4.91%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 92.88%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.